Creo Medical (CREO.L) expects FY revenue growth of 50%-60% in line with guidance
Reuters says Creo Medical is confident of delivering FY revenue growth of 50% to 60% and expects Q3-26 year-to-date revenue growth of about 50%. H1 adjusted EBIT was GBP -4.9 million.